Insilico Medicine announced that its AI-discovered drug rentosertib, a treatment for idiopathic pulmonary fibrosis, will begin Phase 3 trials in China, with the first patient dosed on Sept. 10, accord…
An experimental AI-designed drug, rentosertib, developed by Insilico Medicine to treat idiopathic pulmonary fibrosis (IPF), appeared to reverse biological-age markers by up to six years in a small hum…
Insilico Medicine's AI-discovered drug rentosertib reduced biological age in a midstage study of 42 patients with chronic lung disease, as measured by six aging clocks, according to an analysis publis…
Insilico Medicine's AI-designed drug rentosertib reduced biological age markers across six AI-powered aging clocks in a 43-patient trial for idiopathic pulmonary fibrosis, results published in Nature …
Insilico Medicine named five humans, including CEO Alex Zhavoronkov, as inventors on a patent for a pulmonary fibrosis drug that its generative AI platform proposed, highlighting a US legal rule that …
Insilico Medicine is previewing a Virtual Aging Cell research direction that incorporates biological age into its virtual-cell models, aiming to improve predictions of cellular responses to genetic ed…
Bora Pharmaceuticals and Insilico Medicine announced a strategic alliance valued at more than $2.5 billion if fully implemented, combining Insilico's Pharma.AI platform for drug discovery with Bora's …
Insilico Medicine and SK Biopharmaceuticals announced a partnership valued at over $2.5 billion to use AI for developing neuroimmune therapies. Insilico will leverage its Pharma.AI platform for drug d…